Carl P. Walther*, Amber S. Podoll*, Kevin W. Finkel* *The University of Texas Health Science Center at Houston Citrate Toxicity During CRRT After Massive.

Slides:



Advertisements
Similar presentations
Regional Citrate Anticoagulation during CVVH in the
Advertisements

Coagulopathy and blood component transfusion in trauma
Acid-Base Disturbances
Blood Bag Coagulation & Preservers Citrate 24 hours 1-6 ºC Heparin 48 hours 1-6 ºC ACD or CPD 21 days 1-6 ºC CPD-A135 days 1-6 ºC CPD-A1+ additive.
Fluid and Electrolyte Management Presented by :sajede sadeghzade.
Brad Beckham T4. Definitions  Major blood loss Hemoglobin concentration below 6-10 g/dl  Massive transfusion in adults >9 erythrocyte units within 24h.
Massive transfusion: New Protocol
Slide 1 of 16 Dose Titration in a Patient with Myelodysplastic Syndromes.
Blood Components Dosage And Their Administration
Sodium bicarbonate to prevent increases in serum creatinine after cardiac surgery: A pilot double- blind, randomized controlled trial Critical Care Medicine.
Heparin in CRRT Benan Bayrakci, McLean Antitrombin 3 Inactive Thrombin (IIa) V, VIII, XIII, Fibrinogen Inactive Factor Xa Common Pathway Inactive.
Intensive care conference: management of acid-base disorders with CRRT International Society of Nephrology 主講人 : R2 顏介立.
Sepsis.
INDICATIONS FOR EMERGENT TRANSFUSIONS Manjushree Matadial DO Saint Joseph Hospital and Medical Center, April 27,2009.
Transfusing tiny soldiers Ramsey C. Tate, MD. Applying combat-derived massive transfusion protocols to pediatric trauma patients.
Recombinant Factor VIIa as Adjunctive Therapy for Bleeding Control in Severely Injured Trauma Patients: Two Parallel Randomized, Placebo-Controlled, Double-
1 Massive Blood Transfusion Massive transfusion, defined as the replacement by transfusion of more than 50 percent of a patient's blood volume in 12 to.
BLOOD TRANSFUSION Begashaw M (MD).
Senior clinician Request: a o 4 units RBC o 2 units FFP Consider: a o 1 adult therapeutic dose platelets o tranexamic acid in trauma patients Include:
Copyright 2008 Society of Critical Care Medicine Management of Life- Threatening Electrolyte and Metabolic Disturbances.
Massive blood transfusion
Iron Toxicity. Overview Principle of the disease Clinical features Diagnosis management.
Transfusion of Blood Product History: 1920:Sodium citrate anticoagulant(10 days storage) 1958: Plastic bag of transfusion 1656: Initial theory and.
ANTICOAGULATION IN CONTINUOUS RENAL REPLACEMENT THERAPY Dawn M Eding RN BSN CCRN Pediatric Critical Care Helen DeVos Children's Hospital.
Fluids and blood products in trauma
Diabetic Ketoacidosis DKA)
Faculty of Allied Medical Science Blood Banking (MLBB 201)
The Clinical Guide “A Guide to Implementing Renal Best Practice in Haemodialysis“ Chapter 5: Anticoagulation Team Leader: Angela Henson Co-authors: Franta.
BLOOD TRANSFUSION NUR 317. TRANSFUSION Infusion of blood products for the purpose of restoring circulating volume.
Blood Banking (MLBB 201). Changes that occur in Stored Blood Prof. Dr. Nadia Aly Sadek Prof. in Haematology and Director of Blood Bank Centre, Medical.
Liver Function Tests. Tests Based on Detoxification and Excretory Functions.
Practical Considerations for CRRT Helen Currier RN, BSN, CNN Nancy McAfee RN, BSN, CNN.
Transfusion Management of Massive Haemorrhage in Adults Patient bleeding / collapses Ongoing severe bleeding eg: 150 mls/min and Clinical shock Administer.
Anticoagulation in CRRT
Immunomodulation of Regional Citrate Anticoagulation in Acute Kidney Injury Requiring Renal Replacement Therapy Sasipha Tachaboon 1, Khajohn Tiranatanakul.
Case: HYPERKALEMIA Group A2.
DIALYSIS SOLUTIONS INC.
Brophy University of Iowa Pediatric CRRT Anticoagulation Patrick Brophy MD Director Pediatric Nephrology University of Iowa- Children’s Hospital PCRRT.
Citrate Anticoagulation
Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU) Screening and randomisation Mette Krag Dept. of Intensive Care 4131 Copenhagen University.
REACTIVE OR PROACTIVE: WHICH IS BEST IN RENAL REPLACEMENT THERAPY PHOSPHATE CONTROL? Joanna Campion-Smith Gurudutta Venkatesha Molly McLaughlin Meeta Mallik.
ANTICOAGULATION PCRRT 2008 Orlando Patrick Brophy MD Director Pediatric Nephrology University of Iowa- Children’s Hospital.
Proposal of a flow-chart to avoid circuit clotting in prolonged intermittent renal replacement therapy (PIRRT): a monocentric experience 1 Vincenzo Cantaluppi,
Regulation of Potassium K+
Results Methods Abstract Number 69 Objectives 1.Nephrol Dial Transplant (2011) 26: 537–543 2.J Support Oncol 2011;9:149–155 3.N Engl J Med. 2009; 361:1627–1638.
ABG INTERPRETATION. BE = from – 2.5 to mmol/L BE (base excess) is defined as the amount of acid that would be added to blood to titrate it to.
The complications can be broadly classified into two categories: Immune Complications Non-immune Complications.
Clinical Laboratory Review for Toxicology
Citrate Continuous Renal Replacement Therapy: Which Protocol? Standard Protocol 1 (SP1) Indication: First hours of therapy Effluent dose target:
Patient Blood Management Guidelines: Module 6 Neonatal and Paediatrics Roles Senior clinician Coordinate team and allocate roles Determine volume and type.
BLOOD TRANSFUSION Ferdi Menda,M.D. Associated Prof of Anesthesiology Yeditepe University.
BLOOD TRANSFUSION Ferdi Menda,M.D. Assistant Prof of Anesthesiology Yeditepe University.
Adenoviral Infection Clearance Via Intravenous Cidofovir Treatment in Two Children on Continuous Veno-venous Hemodiafiltration Alyssa A. Riley, Ayse A.
CARE OF THE PATIENT RECEIVING BLOOD/BLOOD COMPONENTS.
CONTINUOUS RENAL REPLACEMENT THERAPY
CRRT Fundamentals Pre- and Post- Test
ABG INTERPRETATION.
Warfarin Toxicity Treatment & Management
محاسبه حجم خون ازدست رفته در اطفال
Copyright © 2009 American Medical Association. All rights reserved.
Acute Iron Overdose in the Setting of Active Labor with Fetal Umbilical Cord Serum Iron Concentration William Eggleston, Pharm.D.1 and Christine M. Stork,
Cairo-Bishop criteria for TLS
Dr.Mitra Azarasa Fellowship Of Cardiac Anesthesia
Use of NOACs is contraindicated for AF patients with mechanical prosthetic valves or moderate- severe mitral stenosis (usually of rheumatic origin). Although.
OUTCOMES OF REGIONAL CITRATE ANTICOAGULATION (RCA) IN PEDIARTIC CONTINUOUS RENAL REPLACEMENT THERAPY (pCRRT) IN A SINGLE CENTER Issa Alhamoud, Diane Gollhofer,
Figure 1 The burden of chronic kidney disease (CKD)
Søren Marker Jensen Dept. of Intensive Care 4131
Use of recombinant factor VIIa as a rescue treatment for intractable bleeding following repeat aortic arch repair  Greg Stratmann, MD, PhD, Isobel A Russell,
Blood Components Dosage And Their Administration
RCA in continuous RRT: basic principles
Presentation transcript:

Carl P. Walther*, Amber S. Podoll*, Kevin W. Finkel* *The University of Texas Health Science Center at Houston Citrate Toxicity During CRRT After Massive Transfusion Background Regional citrate anticoagulation (RCA) is commonly used in continuous renal replacement therapy (CRRT). Citrate is also used to inhibit coagulation during storage of blood products by chelating calcium (Ca). Fresh frozen plasma (FFP) has the highest concentration of citrate among blood products at approximately 20 mmol/L. 1,2,3 The normal liver rapidly metabolizes citrate to bicarbonate and releases bound Ca, but liver dysfunction reduces this ability and predisposes to citrate toxicity during CRRT with RCA. Citrate toxicity is detected by an elevation in the total to ionized Ca ratio (TCa/iCa). Continuous veno-venous hemofiltration (CVVH) with Ca 1.5 mmol/L was started without anticoagulation. Because of a gastrointestinal hemorrhage, the patient received 10 units (2.6L) of FFP, and one unit of packed red blood cells (PRBC), for a total of approximately 50 mmol of citrate. Figure 2. Serum ionized calcium concentration during the reported period. She developed hypotension and was found to have an iCa level of 0.88 mmol/L, a TCa level of 9.4 mg/dL, and an elevated TCa/iCa ratio of This ratio was significantly higher than prior to the administration of blood products and is above the threshold value for citrate toxicity of 2.5. Two grams (14 mmol) of calcium chloride (CaCl 2 ) were given, and an infusion of CaCl 2 at 1 mmol/hr was started. After the patient received a total of 22 mmol of Ca, iCa was normalized, with reduction of the TCa/iCa ratio below 2.5. The CaCl 2 infusion was stopped. The following day she was given 4 units PRBC and 4 units FFP (approximately 20 mmol citrate), and developed elevated TCa (Figure 1), low iCa (Figure 2) and elevated TCa/iCa ratio, and was re-treated with another bolus and infusion of CaCl 2, for a total of 26 mmol Ca (Figure 3). Figure 1. Total serum calcium concentration during the reported period. Case Report A 51 year-old woman with cirrhosis due to chronic hepatitis B (HBV) was admitted to the intensive care unit for acute liver failure, thought to be due to rapid HBV replication after she stopped taking antiviral medication because of side-effects. During the next two weeks she developed encephalopathy, coagulopathy, lactic acidosis, and oliguric acute kidney injury. The bleeding eventually resolved without intervention. With no further large-volume transfusions, the calcium derangements did not recur. CVVH was continued, but the patient deteriorated and subsequently was transitioned to comfort care. Conclusion Citrate toxicity is not uncommon in patients with liver failure undergoing CRRT with RCA and is monitored by measuring the TCa/iCa ratio. However, as this case illustrates, patients with liver failure who receive massive amounts of blood products should also be monitored for the development of citrate toxicity. Figure 3. Ratio of total to ionized calcium during the reported period. References 1.Guidelines for the use of fresh frozen plasma. Transfusion Medicine. 2: 57-63, Der Meulen, J, Janssen, M, Oe, P: Cardiac arrest during massive plasma exchange for haemolytic-uraemic syndrome. Nephrol Dial Trans 1841, Miller, RD et al. Miller's Anesthesia, 7th ed, Churchill Livingstone. 2009